Speech Treatment for Minimally Verbal Children With ASD and CAS — TxMVASD+CAS  

Autism Spectrum Disorder Clinical Trial

Official title: Speech Treatment for Minimally Verbal Children With ASD and CAS

Status Recruiting

Clinical Trial Summary

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Clinical Trial Description

Although one in four children with autism remain minimally verbal past age five, not all the factors that limit spoken language in these minimally verbal children are known. One powerful contributor may be a motor speech disorder, Childhood Apraxia of Speech (CAS). CAS is an impairment in the ability to plan and sequence for speech, which makes speech inconsistent and imprecise. This project proposes to investigate whether CAS makes the speech of minimally verbal children with autism unintelligible, and then to test whether treating the CAS improves children's speech.

First, a cohort of 20 minimally verbal children with both autism and CAS is identified. The prediction is that the more severe the CAS, the more inconsistent and imprecise a child's speech, and therefore the lower their intelligibility will be. Then, a set of mono- and bisyllabic words is selected that contain the disordered movements that each child shows and use those in treatment.

Treatment will take the form of 15 one-hour sessions where speech practice is embedded in a naturalistic, play-based milieu that is centered on each child's own developmental level. It will involve principles of motor learning (intensive practice of a few words, sometimes all in a row and sometimes mixed up). Different types of cues (touch cues, simultaneous production, etc.) will also be employed to help children say their words correctly, fading back these supports as the child's speech improves. Both of these techniques have been shown to be effective for treating CAS.

Our outcome measures will include both (1) "by-ear" assessments of intelligibility and (2) acoustic and kinematic measurements of children's speech after 15 treatment sessions. The findings will inform clinical practice for minimally verbal children with autism and may lead to the development of novel interventions for this severely affected population. ;

Related Conditions & MeSH terms

• Apraxias
• Autism Spectrum Disorder
• Developmental Verbal Dyspraxia

• NCT number: NCT05066178
• Study type: Interventional
• Source: MGH Institute of Health Professions
• Contact: Karen V Chenausky, Ph.D.
• Phone: 617-726-2405
• Email: kvchenausky@mghihp.edu
• Status: Recruiting
• Phase: N/A
• Start date: May 1, 2024
• Completion date: November 30, 2024